无干扰素丙型肝炎治疗进展：2014年及以后。 - Suppr

Suppr

超能文献

Advances in interferon-free hepatitis C therapy: 2014 and beyond.

作者信息

Sarkar Souvik, Lim Joseph K

机构信息

Yale Liver Center, Yale University School of Medicine, New Haven, CT.

出版信息

Hepatology. 2014 Apr;59(4):1641-4. doi: 10.1002/hep.27055. Epub 2014 Mar 3.

DOI:10.1002/hep.27055

PMID:24590916

Abstract

摘要

相似文献

Advances in interferon-free hepatitis C therapy: 2014 and beyond.

Hepatology. 2014 Apr;59(4):1641-4. doi: 10.1002/hep.27055. Epub 2014 Mar 3.

Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma.

J Surg Oncol. 2008 Oct 1;98(5):358-62. doi: 10.1002/jso.21111.

Short-term interferon therapy for chronic hepatitis C patients with low viral load.

Hepatogastroenterology. 2004 Jul-Aug;51(58):968-72.

[Thyroid dysfunction in patients with chronic hepatitis C pre and post treatment with interferon].

Rev Esp Enferm Dig. 1996 Jul;88(7):480-4.

High-dose interferon-alpha 2b plus ribavirin combination therapy for GB virus-C/hepatitis G virus infection--a study in patients with chronic hepatitis C.

Hepatogastroenterology. 2003 Mar-Apr;50(50):449-52.

Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon.

Ital J Gastroenterol Hepatol. 1997 Aug;29(4):338-42.

Therapy of hepatitis C: overview.

Hepatology. 1997 Sep;26(3 Suppl 1):71S-77S. doi: 10.1002/hep.510260713.

The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C.

J Hepatol. 1995;23 Suppl 2:8-12.

Therapy for hepatitis B virus infection.

Gastroenterol Clin North Am. 1994 Sep;23(3):581-601.

Future studies of combination therapy for chronic hepatitis C: optimizing response rates for each hepatitis C population.

J Hepatol. 1995;23 Suppl 2:32-5; discussion 35-6.

引用本文的文献

Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges.

Gastroenterology. 2019 Jan;156(2):431-445. doi: 10.1053/j.gastro.2018.10.024. Epub 2018 Oct 17.

Disparities in hepatitis C testing in U.S. veterans born 1945-1965.

J Hepatol. 2016 Aug;65(2):259-65. doi: 10.1016/j.jhep.2016.04.012. Epub 2016 Apr 27.

Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study.

Medicine (Baltimore). 2015 Oct;94(42):e1837. doi: 10.1097/MD.0000000000001837.

Rescuing compound bioactivity in a secondary cell-based screening by using γ-cyclodextrin as a molecular carrier.

Int J Nanomedicine. 2015 Mar 19;10:2249-59. doi: 10.2147/IJN.S79480. eCollection 2015.

Long-term survival in patients with T2 hepatocellular carcinoma after primary curative resection can be further stratified by tumor size.

Medicine (Baltimore). 2014 Dec;93(27):e203. doi: 10.1097/MD.0000000000000203.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Advances in interferon-free hepatitis C therapy: 2014 and beyond.

作者信息

Sarkar Souvik, Lim Joseph K

机构信息

Yale Liver Center, Yale University School of Medicine, New Haven, CT.

出版信息

Hepatology. 2014 Apr;59(4):1641-4. doi: 10.1002/hep.27055. Epub 2014 Mar 3.

DOI:10.1002/hep.27055

PMID:24590916

Abstract

摘要

相似文献

Advances in interferon-free hepatitis C therapy: 2014 and beyond.

Hepatology. 2014 Apr;59(4):1641-4. doi: 10.1002/hep.27055. Epub 2014 Mar 3.

Response to interferon therapy affects risk factors for postoperative recurrence of hepatitis C virus-related hepatocellular carcinoma.

J Surg Oncol. 2008 Oct 1;98(5):358-62. doi: 10.1002/jso.21111.

Short-term interferon therapy for chronic hepatitis C patients with low viral load.

Hepatogastroenterology. 2004 Jul-Aug;51(58):968-72.

[Thyroid dysfunction in patients with chronic hepatitis C pre and post treatment with interferon].

Rev Esp Enferm Dig. 1996 Jul;88(7):480-4.

High-dose interferon-alpha 2b plus ribavirin combination therapy for GB virus-C/hepatitis G virus infection--a study in patients with chronic hepatitis C.

Hepatogastroenterology. 2003 Mar-Apr;50(50):449-52.

Pilot study on the safety and efficacy of intravenous natural beta-interferon therapy in patients with chronic hepatitis C unresponsive to alpha-interferon.

Ital J Gastroenterol Hepatol. 1997 Aug;29(4):338-42.

Therapy of hepatitis C: overview.

Hepatology. 1997 Sep;26(3 Suppl 1):71S-77S. doi: 10.1002/hep.510260713.

The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C.

J Hepatol. 1995;23 Suppl 2:8-12.

Therapy for hepatitis B virus infection.

Gastroenterol Clin North Am. 1994 Sep;23(3):581-601.

Future studies of combination therapy for chronic hepatitis C: optimizing response rates for each hepatitis C population.

J Hepatol. 1995;23 Suppl 2:32-5; discussion 35-6.

引用本文的文献

Status of Direct-Acting Antiviral Therapy for Hepatitis C Virus Infection and Remaining Challenges.

Gastroenterology. 2019 Jan;156(2):431-445. doi: 10.1053/j.gastro.2018.10.024. Epub 2018 Oct 17.

Disparities in hepatitis C testing in U.S. veterans born 1945-1965.

J Hepatol. 2016 Aug;65(2):259-65. doi: 10.1016/j.jhep.2016.04.012. Epub 2016 Apr 27.

Personalized Therapy of Chronic Hepatitis C and B Dually Infected Patients With Pegylated Interferon Plus Ribavirin: A Randomized Study.

Medicine (Baltimore). 2015 Oct;94(42):e1837. doi: 10.1097/MD.0000000000001837.

Rescuing compound bioactivity in a secondary cell-based screening by using γ-cyclodextrin as a molecular carrier.

Int J Nanomedicine. 2015 Mar 19;10:2249-59. doi: 10.2147/IJN.S79480. eCollection 2015.

Long-term survival in patients with T2 hepatocellular carcinoma after primary curative resection can be further stratified by tumor size.

Medicine (Baltimore). 2014 Dec;93(27):e203. doi: 10.1097/MD.0000000000000203.